FDAnews Drug Daily Bulletin

EMA Committee Recommends Full Approval of Imbruvica to Treat Two Blood Cancers

July 29, 2014
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending the granting of full marketing approval for Pharmacyclics' Imbruvica (ibrutinib) in the EU.
Pharmaceutical Business Review